Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission model

A dynamic transmission model using recent UK epidemiological data demonstrates that implementing the 20-valent pneumococcal conjugate vaccine (PCV20) in children would significantly reduce disease burden and deaths while being cost-saving compared to PCV13 and PCV15, thereby supporting its timely adoption.

The Gist

Imagine the United Kingdom's National Immunisation Programme as a giant, high-tech security system designed to keep a specific type of burglar (pneumococcal bacteria) out of people's homes. For years, this system has been using a "13-lock" key (the PCV13 vaccine) to block 13 specific types of burglars. It worked well, but the burglars are smart; they've started using different keys (new serotypes) that the 13-lock can't stop. In fact, these new, unblocked burglars are now causing more trouble than the old ones.

This paper is like a simulation run by a team of experts (mostly from Pfizer and their partners) to see what happens if the UK switches to a "20-lock" key (the PCV20 vaccine). They wanted to know: Would this new key stop more burglars? Would it save the country money? And how many people would need to get the new key to stop just one bad event?

Here is the breakdown of their findings using simple analogies:

1. The "Bigger Key" Stops More Break-ins

The researchers built a complex computer model (a digital twin of the UK population) to test three scenarios over the next 10 years:

• The Old Key (PCV13): The current standard.
• The Medium Key (PCV15): A slightly bigger key with 15 locks.
• The Big Key (PCV20): The newest, biggest key with 20 locks.

The Result: The "Big Key" (PCV20) was the clear winner. Because it covers more types of burglars, it prevented significantly more cases of disease (like invasive infections, pneumonia, and ear infections) and saved more lives than the other two keys.

2. The "Cost-Saving" Paradox

Usually, buying a bigger, better key costs more money upfront. The PCV20 vaccine is indeed more expensive per dose than the older versions.

However, the study found that the UK would actually save money in the long run. Think of it like buying a high-quality, expensive roof for your house. Even though the roof costs more to install, it prevents so much water damage, mold, and repair bills later that you end up with more money in your pocket than if you had bought a cheap roof that leaked.

The model showed that by preventing so many sick people, the healthcare system would save billions of pounds in hospital bills and treatment costs, easily offsetting the higher price of the vaccine. In economic terms, the new vaccine is "dominant," meaning it is both better for health and cheaper overall.

3. The "Need to Vaccinate" Metric (NNV)

The paper introduces a concept called the "Number Needed to Vaccinate" (NNV). Imagine you are trying to stop a single leak in a dam.

• If you use the Medium Key (PCV15), you might need to patch 9,352 spots to stop just one serious invasive infection.
• If you use the Big Key (PCV20), you only need to patch about 597 spots to stop that same single infection.

In everyday language: The Big Key is roughly 15 times more efficient at stopping serious infections than the Medium Key. You get a much bigger "bang for your buck" in terms of public health protection.

4. Two Ways to Install the Key (1+1 vs. 2+1)

The study also looked at how the vaccine is given to babies.

• The 1+1 Schedule: One dose at 4 months, one booster at 12 months. (This is what the UK currently uses).
• The 2+1 Schedule: Two doses early on (2 and 4 months), plus a booster at 12 months.

The model found that while the 1+1 schedule with the Big Key is still a massive improvement over the old system, the 2+1 schedule is even better. It stops even more disease and saves even more lives. While it costs a bit more to give that extra early dose, the study suggests it's a worthwhile investment because it protects babies during their most vulnerable first year of life more effectively.

5. What the Study Didn't Say (The Limitations)

The authors were careful to note a few things they didn't know:

• The "Unknown" Burglars: They had to guess how well the new key works against the new locks because real-world data isn't fully available yet. They assumed it works as well as the old key did against the old locks.
• The "Post-COVID" World: The model used data from after the pandemic, which is good, but the way people interact (contact patterns) might still be changing, which could affect how the bacteria spread.
• Long-term Effects: The study counted the immediate sickness but didn't fully calculate the long-term damage (like hearing loss from meningitis) or the benefit of reducing antibiotic use, which means the true value of the vaccine might be even higher than they calculated.

The Bottom Line

The paper concludes that swapping the current vaccine for the 20-valent version (PCV20) in the UK is a smart move. It acts like upgrading from a standard lock to a high-security smart lock: it stops more intruders, saves the homeowner (the healthcare system) money in the long run, and does so efficiently, requiring fewer people to be vaccinated to prevent a single tragedy. The study recommends that the UK should consider adopting this new vaccine to keep its population safer and its budget healthier.

Technical Summary

Technical Summary: Projected Health and Economic Impact of PCV20 Vaccination in UK Children

Problem Statement
Despite the long-standing inclusion of pneumococcal conjugate vaccines (PCVs) in the United Kingdom's National Immunisation Programme (NIP) since 2006, the burden of pneumococcal disease remains substantial. Current epidemiology indicates that the disease burden is primarily driven by serotypes not covered by the 13-valent PCV (PCV13). While higher-valent vaccines, specifically the 20-valent PCV (PCV20) and 15-valent PCV (PCV15), have received marketing authorization, their value in the contemporary UK setting has not been fully assessed using recent post-pandemic data. Previous modeling efforts relied on pre-COVID-19 data and did not account for recent schedule changes, such as the transition to a 1+1 dosing schedule and the adjustment of the priming dose timing from 3 to 4 months. Furthermore, while cost-effectiveness is a standard metric, the Number Needed to Vaccinate (NNV) is increasingly utilized by the Joint Committee on Vaccination and Immunisation (JCVI) for decision-making but has not been comprehensively evaluated for PCV20 in the UK.

Methodology
The authors updated a previously published, age-structured dynamic transmission model to reflect UK epidemiology from 2001 to 2023. The model employs a susceptible–infected–susceptible (SIS) structure to project pneumococcal carriage, disease progression, and recovery. Key methodological features include:

• Calibration: The model was calibrated against historical surveillance data for invasive pneumococcal disease (IPD) across five age groups (<5, 5–14, 15–44, 45–64, and 65+ years).
• Vaccine Scenarios: The study compared PCV20 administered under both 1+1 (priming at 4 months, booster at 12 months) and 2+1 (priming at 2 and 4 months, booster at 12 months) schedules against PCV13 and PCV15, both administered under a 1+1 schedule.
• Effectiveness Assumptions: Due to a lack of specific data for PCV15 and PCV20, the model assumed that effectiveness against IPD and carriage for newly covered serotypes in these vaccines is equivalent to PCV13's effectiveness against its specific serotypes (1, 5, 7F, 6A, and 19A).
• Economic Framework: A 10-year time horizon was used from a UK payer perspective. Costs and outcomes were discounted at 3.5% annually. The analysis included vaccination costs, direct medical costs for bacteremia, meningitis, hospitalized pneumonia, and otitis media (OM), as well as quality-adjusted life-years (QALYs).
• Sensitivity and Scenario Analysis: The study conducted deterministic one-way, multivariate probabilistic sensitivity analyses (PSA), and scenario analyses to test uncertainties, including variations in vaccine effectiveness against carriage, time horizons (5 vs. 10 years), and IPD presentation rates.

Key Contributions
This study provides the first comprehensive assessment of PCV20 in the UK using post-COVID-19 epidemiological data and recent dosing schedule parameters. Its primary contributions include:

1. Updated Epidemiological Modeling: Moving beyond pre-pandemic data to reflect current disease burdens and the impact of the 2020/2025 schedule changes.
2. Dual-Schedule Evaluation: Simultaneously evaluating PCV20 under both 1+1 and 2+1 schedules, allowing for a direct comparison of dosing strategies.
3. NNV Estimation: Calculating the Number Needed to Vaccinate to prevent a single case of disease (IPD, pneumonia, OM) or a pneumococcal-related death, offering a transparent metric for population-level efficiency alongside traditional cost-effectiveness ratios.
4. Comprehensive Cost-Effectiveness: Assessing incremental cost-effectiveness ratios (ICERs) against standard willingness-to-pay thresholds (£20,000–£30,000 per QALY).

Results

• Disease Burden Reduction: Over a 10-year horizon, PCV20 (both 1+1 and 2+1) was estimated to avert significantly more cases and deaths than PCV13 or PCV15. Specifically, PCV20 1+1 was projected to avert 309,123 additional cases compared to PCV13 1+1, while PCV20 2+1 was projected to avert 536,570 additional cases.
• Economic Impact: Both PCV20 schedules were found to be "dominant" (more effective and cost-saving) compared to PCV13 and PCV15.
  • Compared to PCV13 1+1, PCV20 1+1 resulted in cost savings of approximately £1.7 billion, and PCV20 2+1 saved approximately £1.5 billion.
  • Compared to PCV15 1+1, PCV20 1+1 saved approximately £1.6 billion, and PCV20 2+1 saved approximately £1.4 billion.
• ICERs: When comparing PCV20 2+1 directly to PCV20 1+1, the 2+1 schedule averted an additional 55,130 cases with an ICER of £13,656 per QALY gained, falling below standard NICE thresholds.
• Number Needed to Vaccinate (NNV): PCV20 demonstrated significantly higher efficiency than PCV15. The NNV to prevent one IPD case with PCV20 1+1 was 597, compared to 9,352 for PCV15. Similarly, the NNV to prevent a pneumococcal-related death was 81 for PCV20 1+1 versus 1,192 for PCV15.
• Robustness: Sensitivity and scenario analyses confirmed that PCV20 remained dominant across various assumptions, including reduced effectiveness against carriage and shorter time horizons.

Significance and Claims
The authors claim that the implementation of pediatric PCV20 in the UK NIP could deliver substantial health gains while improving economic efficiency. The study supports the timely adoption of PCV20, suggesting that continued reliance on PCV13 may result in avoidable public health and economic consequences.

The paper highlights that PCV20 offers a "dominant" strategy over lower-valent alternatives, driven by broader serotype coverage and indirect herd effects. The inclusion of the 2+1 schedule analysis suggests that while the 1+1 schedule is cost-saving, the 2+1 schedule offers additional clinical benefits at a cost-effective rate, potentially providing enhanced protection during the first year of life. The authors conclude that these findings, derived from conservative assumptions and recent data, underscore the robustness of PCV20 as an economically efficient option for maximizing public health benefits in the UK. They also note that the study likely underestimates the full value of PCV20 by not accounting for long-term sequelae of meningitis or reductions in antibiotic prescribing.